ReviewPurinergic signalling2026
The P2X7 receptor/NLRP3 inflammasome signaling axis in sepsis: molecular mechanisms, organ-specific pathophysiology, and emerging therapeutic strategies.
Review in Purinergic signalling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- ATP is not always pro-inflammatory: rethinking purinergic signalling in cancer and autoimmunity.Purinergic signalling · 2026Review
- PathSepsisNet: a pathway-aware temporal graph attention network integrating inflammatory crosstalk dynamics for early prediction of multi-organ dysfunction in sepsis.Purinergic signalling · 2026Article
- The NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review.Critical care (London, England) · 2026Review
- Assessment of methylene blue and NAD on LPS-induced acute brain injury: effects on neuroinflammation, oxidative stress, and blood-brain barrier integrity in a rat endotoxemia model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Inflammasomes in Sjögren's Disease: Exploring the Therapeutic Value.International journal of molecular sciences · 2026Review
- Probiotic Supplementation Attenuates Polystyrene Nanoplastic-Induced Pancreatic Injury through Modulation of Oxidative Stress, Inflammation, and P2X7 Receptor/Caspase-1 Signaling Pathway in Rats.Probiotics and antimicrobial proteins · 2026Article
- NLR Inflammasomes in Viral Infections: From Molecular Mechanisms to Therapeutic Interventions.Viruses · 2026Review
- Review
- Inhibiting the P2X7R-NLRP3 inflammasome pathway regulates CXCL16 to alleviate podocyte injury in mice with adriamycin nephropathy.Scientific reports · 2026Article
- Crosstalk between innate immune signaling pathways and integrated TLR, NLRP3 inflammasome, cGAS-STING, and NF-κB networks in sepsis.Frontiers in cell and developmental biology · 2026Review
- Pathological triad of perioperative acute kidney injury: renal microcirculatory hypoxia, mitochondrial damage, and immuno-metabolic reprogramming.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sepsis remains a leading cause of mortality in intensive care units worldwide, representing life-threatening organ dysfunction arising from dysregulated host responses to infection. The purinergic P2X7 receptor (P2X7R) and the NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammasome have emerged as critical regulators of inflammatory responses during sepsis pathogenesis. Extracellular adenosine triphosphate (ATP), released as a danger-associated molecular pattern from damaged and dying cells, activates the P2X7R, triggering potassium efflux that serves as the cardinal signal for NLRP3 inflammasome assembly. The activated inflammasome complex mediates caspase-1-dependent proteolytic maturation of the proinflammatory cytokines interleukin-1β (IL-1β) and IL-18, while simultaneously inducing gasdermin D (GSDMD)-mediated pyroptotic cell death-an inflammatory form of programmed cell death characterized by membrane pore formation, cellular swelling, and release of intracellular contents. Paradoxically, emerging evidence indicates that excessive P2X7R activation during sepsis progression induces profound mitochondrial dysfunction in circulating monocytes, leading to impaired NLRP3 inflammasome function and a state of immunoparalysis that coincides with an increased mortality. This comprehensive review examines the molecular mechanisms governing P2X7/NLRP3 signaling in sepsis; critically evaluates its dual and seemingly contradictory roles in hyperinflammation versus immunosuppression; delineates organ-specific manifestations across the lung, kidney, heart, brain, liver, and intestine; and systematically evaluates emerging therapeutic strategies including direct NLRP3 inhibitors such as MCC950, selective P2X7R antagonists, IL-1 receptor blockade, GSDMD inhibitors, and natural compounds with inflammasome-modulating properties. Understanding the temporal dynamics of this signaling axis is crucial for developing precision-targeted interventions that appropriately balance pathogen clearance with prevention of excessive inflammatory tissue damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.